长春西汀联合阿加曲斑在急性脑梗死患者中的临床效果及对神经功能缺损评分的影响  

The clinical effect of vinpocetine combined with argatrocar in patients with acute cerebral infarction and its influence on NIHSS score

作　　者：赵君 吴卫文 Zhao Jun;Wu Weiwen(Department of Neurology,Qingpu Branch,Zhongshan Hospital Affiliated to Fudan University,Shanghai 201700,China)

机构地区：[1]复旦大学附属中山医院青浦分院神经内科,上海201700

出　　处：《山西医药杂志》2024年第1期22-25,共4页Shanxi Medical Journal

摘　　要：目的探讨长春西汀联合阿加曲斑在急性脑梗死患者中的临床效果及对神经功能缺损(NIHSS)评分的影响。方法选择2020年1月至2022年1月急性脑梗死患者108例作为对象,随机数字表法分为2组,各54例。2组均给予常规方法治疗,长春西汀组采用长春西汀注射液治疗,联合用药组为长春西汀联合阿加曲斑治疗,2周干预后评价患者效果并进行12个月随访,比较2组NIHSS、Barthel指数(BI)、改良Rankin量表(mRS)评分、血液流变学、不良反应及远期预后。结果联合用药组为长春西汀用药4周后NIHSS、mRS低于长春西汀组(P<0.05);BI评分高于长春西汀组(P<0.05);2组用药4周后血液流变学均降低;联合用药组用药4周后血浆黏度、红细胞压积、纤维蛋白原及全血黏度水平均低于长春西汀组(P<0.05);2组用药期间药物不良反应发生率比较差异无统计学意义(P>0.05);联合用药组用药结束后随访8及12个月复发率低于长春西汀组(P<0.05)。结论长春西汀联合阿加曲斑用于急性脑梗死患者中有助于减轻神经缺损,提高患者生活能力,可改善血液流变学水平,药物安全性较高,能获得良好的远期预后,值得推广应用。Objective To investigate the clinical effect of argatroban in patients with acute cerebral infarction and its influence on neurological deficit(NIHSS)score.Methods One hundred and eight patients with acute cerebral infarction from January 2020 to January 2022 were selected as subjects and divided into two groups(54 cases in each)by random number table method.The two groups were treated with conventional methods.The vinpocetine group was treated with vinpocetine injection,and combined medication group was treated with vinpocetine and argatroban.After 2 weeks of intervention,the patients′effect was evaluated and were followed up for 12 months.NIHSS and Barthel.Index(BI),modified Rankin scale(mRS)score,hemorheology,adverse reactions and long-term prognosis in the two groups were compared.Results NIHSS and mRS in combined medication group were lower than those in the vinpocetine group(P<0.05)after 4 weeks of treatment,the BI score was higher than that in the vinpocetine group(P<0.05),the blood rheology of the two groups was obtained after 4 weeks of treatment decrease.Plasma viscosity,hematocrit,fibrinogen and whole blood viscosity levels in combined medication group were lower than those in the vinpocetine group after 4 weeks of medication(P<0.05),the incidence of adverse drug reactions during the two groups was not statistically significant(P>0.05),The recurrence rate in the 8 and 12-month follow-up period after the end of medication in the combined medication group was lower than that in the vinpocetine group(P<0.05).Conclusion The use of argatroban in patients with acute cerebral infarction can help reduce neurological deficits,improve patients′living ability,improve blood rheology,and have high drug safety and good long-term prognosis.It is worthy of popularization and application.

关 键 词：脑梗死 神经病学表现 阿加曲斑 血液流变学 生活能力 不良反应 远期预后 

分 类 号：R743.33[医药卫生—神经病学与精神病学]